Loading…

In vivo pharmacokinetics of selective mu-opioid peptide agonists

Recent evidence suggests that highly selective mu-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the m...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of pharmacology and experimental therapeutics 2001-07, Vol.298 (1), p.57-61
Main Authors: Szeto, H H, Lovelace, J L, Fridland, G, Soong, Y, Fasolo, J, Wu, D, Desiderio, D M, Schiller, P W
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 61
container_issue 1
container_start_page 57
container_title The Journal of pharmacology and experimental therapeutics
container_volume 298
creator Szeto, H H
Lovelace, J L
Fridland, G
Soong, Y
Fasolo, J
Wu, D
Desiderio, D M
Schiller, P W
description Recent evidence suggests that highly selective mu-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) > 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO). In addition, [Dmt1]DALDA was 3000-fold more potent than morphine when administered intrathecally. A potential problem with peptide analogs as therapeutic agents is their susceptibility to enzymatic degradation in vivo and short elimination half-lives. In this study, we compared the stability of DAMGO, DALDA, and [Dmt1]DALDA after systemic administration in sheep. Peptide concentrations were measured using high performance liquid chromatography-mass spectrometry. When incubated in sheep blood at 37 degrees C, DAMGO, DALDA, and [Dmt1]DALDA were stable over 2 h. When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume. Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively. The half-lives of DALDA and [Dmt1]DALDA are even longer than morphine or meperidine in sheep. These favorable pharmacokinetic properties of DALDA and [Dmt1]DALDA, together with their mu-selectivity, potency, and long duration of action, make them ideal candidates as opioid analgesics.
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_70940657</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70940657</sourcerecordid><originalsourceid>FETCH-LOGICAL-p207t-832b044a93c1a4acb913eac23bb85d62f0f4a27c859dde4a9c0e41f505ec83733</originalsourceid><addsrcrecordid>eNo1z0tLxDAUhuEsFGcc_QuSlbvCya2XnTJ4GRhwo-tympxqtG1ikw747x1wXH2bhw_eM7YGkLJQpjQrdpnSJ4DQulQXbCWEhtpIs2Z3u4kf_CHw-IHziDZ8-Ymyt4mHnicayGZ_ID4uRYg-eMcjxewdcXwPk085XbHzHodE16fdsLfHh9ftc7F_edpt7_dFlFDlolayA62xUVagRts1QhFaqbquNq6UPfQaZWVr0zhHR2eBtOgNGLK1qpTasNu_3ziH74VSbkefLA0DThSW1FbQaChNdYQ3J7h0I7k2zn7E-af9b1a_9_5SMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70940657</pqid></control><display><type>article</type><title>In vivo pharmacokinetics of selective mu-opioid peptide agonists</title><source>Freely Accessible Medical Journals at publisher websites</source><creator>Szeto, H H ; Lovelace, J L ; Fridland, G ; Soong, Y ; Fasolo, J ; Wu, D ; Desiderio, D M ; Schiller, P W</creator><creatorcontrib>Szeto, H H ; Lovelace, J L ; Fridland, G ; Soong, Y ; Fasolo, J ; Wu, D ; Desiderio, D M ; Schiller, P W</creatorcontrib><description>Recent evidence suggests that highly selective mu-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) &gt; 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO). In addition, [Dmt1]DALDA was 3000-fold more potent than morphine when administered intrathecally. A potential problem with peptide analogs as therapeutic agents is their susceptibility to enzymatic degradation in vivo and short elimination half-lives. In this study, we compared the stability of DAMGO, DALDA, and [Dmt1]DALDA after systemic administration in sheep. Peptide concentrations were measured using high performance liquid chromatography-mass spectrometry. When incubated in sheep blood at 37 degrees C, DAMGO, DALDA, and [Dmt1]DALDA were stable over 2 h. When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume. Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively. The half-lives of DALDA and [Dmt1]DALDA are even longer than morphine or meperidine in sheep. These favorable pharmacokinetic properties of DALDA and [Dmt1]DALDA, together with their mu-selectivity, potency, and long duration of action, make them ideal candidates as opioid analgesics.</description><identifier>ISSN: 0022-3565</identifier><identifier>PMID: 11408525</identifier><language>eng</language><publisher>United States</publisher><subject>Analgesics - blood ; Analgesics - pharmacokinetics ; Animals ; Enkephalin, Ala-MePhe-Gly- - blood ; Enkephalin, Ala-MePhe-Gly- - pharmacokinetics ; Female ; Oligopeptides - blood ; Oligopeptides - pharmacokinetics ; Receptors, Opioid, mu - agonists ; Receptors, Opioid, mu - metabolism ; Sheep - metabolism</subject><ispartof>The Journal of pharmacology and experimental therapeutics, 2001-07, Vol.298 (1), p.57-61</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11408525$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szeto, H H</creatorcontrib><creatorcontrib>Lovelace, J L</creatorcontrib><creatorcontrib>Fridland, G</creatorcontrib><creatorcontrib>Soong, Y</creatorcontrib><creatorcontrib>Fasolo, J</creatorcontrib><creatorcontrib>Wu, D</creatorcontrib><creatorcontrib>Desiderio, D M</creatorcontrib><creatorcontrib>Schiller, P W</creatorcontrib><title>In vivo pharmacokinetics of selective mu-opioid peptide agonists</title><title>The Journal of pharmacology and experimental therapeutics</title><addtitle>J Pharmacol Exp Ther</addtitle><description>Recent evidence suggests that highly selective mu-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) &gt; 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO). In addition, [Dmt1]DALDA was 3000-fold more potent than morphine when administered intrathecally. A potential problem with peptide analogs as therapeutic agents is their susceptibility to enzymatic degradation in vivo and short elimination half-lives. In this study, we compared the stability of DAMGO, DALDA, and [Dmt1]DALDA after systemic administration in sheep. Peptide concentrations were measured using high performance liquid chromatography-mass spectrometry. When incubated in sheep blood at 37 degrees C, DAMGO, DALDA, and [Dmt1]DALDA were stable over 2 h. When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume. Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively. The half-lives of DALDA and [Dmt1]DALDA are even longer than morphine or meperidine in sheep. These favorable pharmacokinetic properties of DALDA and [Dmt1]DALDA, together with their mu-selectivity, potency, and long duration of action, make them ideal candidates as opioid analgesics.</description><subject>Analgesics - blood</subject><subject>Analgesics - pharmacokinetics</subject><subject>Animals</subject><subject>Enkephalin, Ala-MePhe-Gly- - blood</subject><subject>Enkephalin, Ala-MePhe-Gly- - pharmacokinetics</subject><subject>Female</subject><subject>Oligopeptides - blood</subject><subject>Oligopeptides - pharmacokinetics</subject><subject>Receptors, Opioid, mu - agonists</subject><subject>Receptors, Opioid, mu - metabolism</subject><subject>Sheep - metabolism</subject><issn>0022-3565</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><recordid>eNo1z0tLxDAUhuEsFGcc_QuSlbvCya2XnTJ4GRhwo-tympxqtG1ikw747x1wXH2bhw_eM7YGkLJQpjQrdpnSJ4DQulQXbCWEhtpIs2Z3u4kf_CHw-IHziDZ8-Ymyt4mHnicayGZ_ID4uRYg-eMcjxewdcXwPk085XbHzHodE16fdsLfHh9ftc7F_edpt7_dFlFDlolayA62xUVagRts1QhFaqbquNq6UPfQaZWVr0zhHR2eBtOgNGLK1qpTasNu_3ziH74VSbkefLA0DThSW1FbQaChNdYQ3J7h0I7k2zn7E-af9b1a_9_5SMQ</recordid><startdate>20010701</startdate><enddate>20010701</enddate><creator>Szeto, H H</creator><creator>Lovelace, J L</creator><creator>Fridland, G</creator><creator>Soong, Y</creator><creator>Fasolo, J</creator><creator>Wu, D</creator><creator>Desiderio, D M</creator><creator>Schiller, P W</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20010701</creationdate><title>In vivo pharmacokinetics of selective mu-opioid peptide agonists</title><author>Szeto, H H ; Lovelace, J L ; Fridland, G ; Soong, Y ; Fasolo, J ; Wu, D ; Desiderio, D M ; Schiller, P W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p207t-832b044a93c1a4acb913eac23bb85d62f0f4a27c859dde4a9c0e41f505ec83733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Analgesics - blood</topic><topic>Analgesics - pharmacokinetics</topic><topic>Animals</topic><topic>Enkephalin, Ala-MePhe-Gly- - blood</topic><topic>Enkephalin, Ala-MePhe-Gly- - pharmacokinetics</topic><topic>Female</topic><topic>Oligopeptides - blood</topic><topic>Oligopeptides - pharmacokinetics</topic><topic>Receptors, Opioid, mu - agonists</topic><topic>Receptors, Opioid, mu - metabolism</topic><topic>Sheep - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szeto, H H</creatorcontrib><creatorcontrib>Lovelace, J L</creatorcontrib><creatorcontrib>Fridland, G</creatorcontrib><creatorcontrib>Soong, Y</creatorcontrib><creatorcontrib>Fasolo, J</creatorcontrib><creatorcontrib>Wu, D</creatorcontrib><creatorcontrib>Desiderio, D M</creatorcontrib><creatorcontrib>Schiller, P W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szeto, H H</au><au>Lovelace, J L</au><au>Fridland, G</au><au>Soong, Y</au><au>Fasolo, J</au><au>Wu, D</au><au>Desiderio, D M</au><au>Schiller, P W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vivo pharmacokinetics of selective mu-opioid peptide agonists</atitle><jtitle>The Journal of pharmacology and experimental therapeutics</jtitle><addtitle>J Pharmacol Exp Ther</addtitle><date>2001-07-01</date><risdate>2001</risdate><volume>298</volume><issue>1</issue><spage>57</spage><epage>61</epage><pages>57-61</pages><issn>0022-3565</issn><abstract>Recent evidence suggests that highly selective mu-opioid agonists may provide good analgesia with less development of tolerance and dependence. H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA) were found to display high binding affinity and much greater selectivity for the mu-opioid receptor (K(i)delta/K(i)mu) &gt; 10,000) compared with H-Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO). In addition, [Dmt1]DALDA was 3000-fold more potent than morphine when administered intrathecally. A potential problem with peptide analogs as therapeutic agents is their susceptibility to enzymatic degradation in vivo and short elimination half-lives. In this study, we compared the stability of DAMGO, DALDA, and [Dmt1]DALDA after systemic administration in sheep. Peptide concentrations were measured using high performance liquid chromatography-mass spectrometry. When incubated in sheep blood at 37 degrees C, DAMGO, DALDA, and [Dmt1]DALDA were stable over 2 h. When given intravenously to sheep, the apparent volume of distribution was 50 to 80 ml/kg for all three peptides, suggesting that distribution was limited to blood volume. Plasma clearance of DAMGO (223 ml/kg/h) was 10-fold faster than DALDA and [Dmt1]DALDA (24 ml/kg/h), and their elimination half-lives were 0.24, 1.5, and 1.8 h, respectively. The half-lives of DALDA and [Dmt1]DALDA are even longer than morphine or meperidine in sheep. These favorable pharmacokinetic properties of DALDA and [Dmt1]DALDA, together with their mu-selectivity, potency, and long duration of action, make them ideal candidates as opioid analgesics.</abstract><cop>United States</cop><pmid>11408525</pmid><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3565
ispartof The Journal of pharmacology and experimental therapeutics, 2001-07, Vol.298 (1), p.57-61
issn 0022-3565
language eng
recordid cdi_proquest_miscellaneous_70940657
source Freely Accessible Medical Journals at publisher websites
subjects Analgesics - blood
Analgesics - pharmacokinetics
Animals
Enkephalin, Ala-MePhe-Gly- - blood
Enkephalin, Ala-MePhe-Gly- - pharmacokinetics
Female
Oligopeptides - blood
Oligopeptides - pharmacokinetics
Receptors, Opioid, mu - agonists
Receptors, Opioid, mu - metabolism
Sheep - metabolism
title In vivo pharmacokinetics of selective mu-opioid peptide agonists
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A49%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vivo%20pharmacokinetics%20of%20selective%20mu-opioid%20peptide%20agonists&rft.jtitle=The%20Journal%20of%20pharmacology%20and%20experimental%20therapeutics&rft.au=Szeto,%20H%20H&rft.date=2001-07-01&rft.volume=298&rft.issue=1&rft.spage=57&rft.epage=61&rft.pages=57-61&rft.issn=0022-3565&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E70940657%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p207t-832b044a93c1a4acb913eac23bb85d62f0f4a27c859dde4a9c0e41f505ec83733%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70940657&rft_id=info:pmid/11408525&rfr_iscdi=true